Compare UFPI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPI | CRSP |
|---|---|---|
| Founded | 1955 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.9B |
| IPO Year | 2011 | 2016 |
| Metric | UFPI | CRSP |
|---|---|---|
| Price | $85.60 | $51.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 17 |
| Target Price | ★ $104.33 | $70.29 |
| AVG Volume (30 Days) | 325.8K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.00 | N/A |
| Revenue | ★ $3,941,182,000.00 | $289,590,000.00 |
| Revenue This Year | $2.04 | $807.72 |
| Revenue Next Year | $5.61 | $172.52 |
| P/E Ratio | $18.00 | ★ N/A |
| Revenue Growth | 21.62 | ★ 9169.85 |
| 52 Week Low | $84.82 | $33.03 |
| 52 Week High | $118.00 | $78.48 |
| Indicator | UFPI | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 47.95 |
| Support Level | N/A | $50.91 |
| Resistance Level | $94.30 | $60.45 |
| Average True Range (ATR) | 2.99 | 2.70 |
| MACD | -0.74 | -0.45 |
| Stochastic Oscillator | 5.53 | 23.22 |
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate. It describes itself as an innovation company, a logistics company, a design company, an engineering and value-added product and solutions company.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.